“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Still, the lack of US approval and the ongoing demand for GLP-1s has pressured the company's stock — which is down 96% to less than $0.50 per share since it de-SPACed and went public in April 2021.